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We demonstrate the utility of microgel core/shell structures
conjugated to fibrin-specific peptides as fibrinolytic agents.
Poly(N-isopropylmethacrylamide) (pNIPMAm) based microgels
conjugated to the peptide GPRPFPAC (GPRP) were observed to
bring about fibrin clot erosion, merely through exploitation of the
dynamic nature of the clots. These results suggest the potential
utility of peptide-microgel hybrids in clot disruption and clotting
modulation.
Fibrin is a biopolymer that plays a vital role in hemostasis. In
the occurrence of an injury, fibrinogen, its soluble precursor, is
enzymatically converted to insoluble fibrin.1 A delicate balance
between the formation of fibrin clots and their dissolution is
critical for maintaining normal bodily function. Dissolution of
clots in the body is carried out by the fibrinolytic system, which
primarily functions via the action of plasmin, through
activation of its precursor plasminogen. The presence of
abnormal clots or thrombi leads to physiological states such as
deep vein thrombosis, atherosclerosis and strokes. In order to
dissolve such thrombi, plasminogen activators are commonly
used. However, direct intravenous administration of these
agents can cause off-target effects and lead to massive
hemorrhage.2 In order to increase the efficacy of these agents
and reduce off-target effects, a number of target-specific
delivery agents have been developed.3-5
Microgels or colloidally stable hydrogel microparticles have
been utilized for the targeted delivery of therapeutics in the
past. A number of these studies have involved the utilization of
ligands or moieties such as proteins or peptides for targeting,
while using a separate therapeutic agent that is generally
encapsulated within the microgel matrix.6-8 However, there are

very few reports on the utilization of the therapeutic ability of
the microgel-ligand conjugates themselves, without a
9
supplemental therapeutic agent. The elimination of variables
associated with the release of a loaded therapeutic could, in
principle, result in a more predictable system having a more
tightly-controlled function. The interactions of colloidal
particles with pre-formed fibrin clots have been studied
10, 11
before.
Additionally, colloids have also been employed as
12, 13
imaging agents targeted to fibrin.
Herein, we present core/shell (C/S) microgels to be used in
fibrinolysis. The grafting of the fibrin-specific peptide GPRP
(fibrin knob ‘A’ mimic) to microgels generated conjugates that
successfully disrupted fibrin clots, presumably via competitive
binding to the holes ‘a’ in fibrin. These results are promising
because this system exploits the nature of fibrin as an
equilibrium polymer14 in order to cause clot disruption. The
occurrence of this disruption in the presence of micromolar
concentrations of targeting peptide, in the absence of an
external fibrinolytic agent, demonstrates the novelty and
potential utility of this system.
Particles in three size ranges were synthesized to analyze
the influence of microgel size on their interactions with fibrin
clots. We hypothesized that the porosity of fibrin clots would
lead to differences in particle residence time. The microgels
were synthesized to have shells with carboxylic acid
functionalities that later facilitated conjugation of the fibrinspecific peptides to the microgels.
C/S microgels were synthesized using a seed-and-feed
approach15 (Scheme S1, ESI). The synthesis conditions for small
(S C/S), intermediate (I C/S), and large (L C/S) particles are
shown in Table 1. Their pH responsivity, sizes and
polydispersities were analyzed via Dynamic Light Scattering,
and their spherical profiles were examined by Atomic Force
Microscopy (Fig. S1 and S2, ESI). Rhodamine was incorporated
in a polymerizable form (methacryloxyethyl thiocarbamoyl
rhodamine B, mRhoB) while synthesizing the cores, to aid
microgel visualization in flow experiments.
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Table 1. Synthesis conditions for small, intermediate and large Core and C/S microgels

Volume
of core
solution

Microgel type

[NIPMAm]

[BIS]

[mRhoB]

[AAc]

[SDS]

[APS]

(mol%)

(mol%)

(mM)

(mol%)

(mM)

(mM)

RH
(nm) at
pH 7*

(mL)
Coreα

-

98

2

0.1

-

8

8

-

C/Sβ

10

93

2

-

5

2

0.5

102±3

Coreα

-

98

2

0.1

-

2

2

-

C/Sβ

10

93

2

-

5

2

0.5

391±18

Coreα

-

98

2

0.1

-

0.5

0.5

-

C/Sβ

10

93

2

-

5

2

0.5

591±39

S C/S

I C/S

L C/S
α

[Total monomer] = 140 mM
[Total monomer] = 50 mM
Temperature = 70 °C
*Measurements in phosphate buffer (50 mM ionic strength)

β

The development of an effective, microgel-based system for
targeted delivery of thrombolytic agents to fibrin clots requires
an investigation into microgel localization in and around clots.
This is essential to determine the efficacy of microgels for the
purpose of fibrinolysis, because the rate of clot degradation
will depend on the region in the clot from where it
commences, and on the manner of its progression. The
interplay between microgel size and fibrin clot porosity is thus
crucial, particularly because microgels are deformable and
hence can undergo more intricate interactions with the clots
than comparable hard sphere colloids.9, 16
The porosity of a fibrin clot depends on the clot formation
conditions.17-19 In this study, the concentration of fibrinogen
used for clot formation was 3 mg/mL, which is close to the
physiological range of ~2.5 mg/mL; the clots were made using
1 U/mL thrombin.
Scheme 1 represents the experimental set up for the flow
studies. In a typical experiment, the permeability of fibrin clots
was first analyzed using Darcy’s law, which relates the average
interstitial fluid velocity to permeability of the medium. The
average value of Darcy’s constant ‘k’, i.e. permeability, for all

clots used in three trials of the experiment was found to be
-13
2
(4.027 ± 0.389) × 10 m , which is in the same range as values
obtained for similarly prepared fibrin clots in previous
11, 20
studies.
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Scheme 1. Experimental setup used for examination of perfusion through fibrin clots

respective (S C/S, I C/S, or L C/S) 0.1 mg/mL reservoir solutions.
The results obtained from three trials are presented in Fig. 1.

In every trial, once uniformity in permeabilities was ensured,
microgel solutions were allowed to flow through the
respective clots. Following equilibration, eluents were
collected at 30 min intervals (60 min, if necessary for collection
of sufficient eluent for analysis), and were analyzed based on
the fluorescence of mRhoB at λex = 540 nm and λem = 575 nm.
All fluorescence values were normalized to those of the
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Figure 1. Eluents collected at specific time points following
flow of microgel solutions through fibrin clots demonstrated
differential microgel-clot interactions based on microgel size.
Minimal, strong and no interactions were shown by S C/S, I C/S
and L C/S microgels, respectively, owing to their size relative to
clot porosity.
The flow studies revealed differences in microgel passage
and residence within fibrin clots based on microgel
dimensions. S C/S microgels were observed to pass through
the clots easily, appearing in the eluent almost immediately.
This suggests that these particles had minimal interactions
with the clot, possibly due to their diameters being
significantly smaller than the average pore size of the clot. I
C/S microgels traversed through the clot slower than the S C/S
microgels, appearing in the eluent only beyond the 1 h time
point and in seemingly smaller numbers. This suggests that
their dimensions may be in the range of the average pore size
of fibrin clots formed under the aforementioned conditions.
Thus, I C/S microgels appear to interact strongly with clot
fibers. L C/S microgels were unable to penetrate the clot and
did not appear in the eluent in the 5 h time frame of the
experiment. Instead, these microgels concentrated at the front
interface of the clot, forming a macroscopically visible
boundary (visualized via the color of mRhoB). Conjugates of
these microgels with fibrin-specific ligands could constitute a
toolbox for targeting clots of different architectures. S C/S
microgels could be utilized for facilitating fibrinolysis of dense
clots with small pore sizes, due to their ability to target the
interior regions of such clots. L C/S microgels on the other
hand, would be better suited for initiating fibrinolysis at the
surfaces of such clots, or in the internal regions of clots with
larger pore sizes.

Keeping the above results in mind, fibrin specificity was
imparted to the L C/S microgels by conjugating peptide
mimics of fibrin knobs ‘A’ and ‘B’ with amino acid
sequences GPRPFPAC (GPRP) and AHRPYAAC (AHRP),
respectively. During the polymerization of fibrinogen, the
fibrinopeptides in the center of the molecule are cleaved by
the proteolytic action of thrombin. This leads to the
generation of ‘free’ knobs ‘A’ and ‘B’, which specifically
interact with the holes ‘a’ and ‘b’ present at the ends of the
fibrinogen molecules, eventually forming fibrin.1 Exposed
holes ‘a’ and ‘b’ are present in the fibrin structure even
after polymerization. Their presence, and the specific A:a
and B:b knob:hole interactions have been exploited in this
study. The aforementioned peptide mimics and other
similar sequences have been studied for their fibrin
specificity in the past.21, 22 A control peptide GPSP
(GPSPFPAC) was also microgel conjugated to investigate
the impact of a non-binding peptide. This led to the
generation of L C/S-GPRP, L C/S-GPSP and L C/S-AHRP
conjugates. The purified microgel-peptide conjugates were
then used in a flow study set up similar to the one
represented in Scheme 1.
The flow studies were performed with fibrin clots made
using 2 mg/mL fibrinogen and 1 U/mL thrombin. Prior to
administering the flow of microgel-peptide conjugates
through the clots, permeability studies were conducted on
the clots to ensure uniformity. The Darcy constants for
trials 1 and 2 represented in Fig. 2 were calculated to be
(6.3 ± 0.18) × 10-13 m2 and (8.17 ± 0.30) × 10-13 m2,
respectively. Following this, the buffer in the reservoirs was
replaced with solutions of L C/S, L C/S-GPRP, L C/S-GPSP
and L C/S-AHRP microgels, all at concentrations of 0.1
mg/mL. The clots were allowed to equilibrate for 10 min,
after which flow rates of the microgel solutions through the
clots were measured at 10 min intervals. The results of
these measurements are presented in Fig. 2.
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Figure 2. Trial 1 (A) and trial 2 (B) for flow rate measurements of microgel solutions through fibrin clots. Gray lines indicate flow
rate of 1X HEPES buffer through the fibrin clots. Pictures of clots after passage of L C/S (C), L C/S-GPSP (D), L C/S-AHRP (E) and L
C/S-GPRP (F) solutions for 100 min, taken during trial 1. Red arrows indicate extent of microgel passage through clots, bringing
about partial (D, E) or complete (F) clot disruption.
Flow rate measurements over time and pictures of clots
taken revealed an initial gradual increase in the flow rates of
the solutions, followed by the complete disruption of fibrin
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clots by L C/S-GPRP microgels over the course of the
experiment (Fig. 2A, B, F). The commencement of disruption is
at the time point where the increase in flow rate is appreciably
higher than that of passage of HEPES buffer through the fibrin
clot. Beyond this point, there is a dramatic increase in flow
rate signaling complete clot disruption. This progression can
also be observed in Supplementary Movie M1, obtained
through a time lapse recording. Additionally, it can be followed
via a decrease in the size of the clot, from 1.50 cm at the
beginning of the experiment to 1.32 cm, 1.20 cm, 1.05 cm,
0.85 cm and 0.53 cm corresponding to the 20 min, 40 min, 60
min, 80 min and 100 min time points respectively. Fig. 2C
demonstrates the integrity of the fibrin clot subsequent to
flow of the L C/S microgel solution through it. This can also be
witnessed quantitatively via the consistent values of flow rate
(Fig. 2A, B). These

observations allow the elimination of shear stress as a factor
involved in the clot disruption. Therefore, the fibrinolysis can
be accounted for primarily by the interactions of the L C/SGPRP microgels with the clots, and can be explained in the
following manner.
It has been assumed for some time that fibrin clot
formation is irreversible and that clot disruption can occur only
in the presence of the active enzyme plasmin or under nonphysiological conditions. The presence of the tetrapeptide
GPRP (tGPRP) and PEGylated GPRP during polymerization has
been known to inhibit polymer formation through competition
with the knobs ‘A’ for interactions with the complementary
22, 23
holes.
However, after clot formation, the effect of such
peptides on fibrin has only been studied briefly. In 2012,
Chernysh et al. demonstrated that fibrin clots behave as
14
equilibrium polymers.
They hypothesized that fibrin
monomers and/or oligomers continually dissociate and
associate with the formed fibers. Bale et al. observed a
decrease in storage moduli of fibrin clots when 5.8 mM tGPRP
solution was diffused into them, eventually leading to clot
24
liquefaction after two days. It is worthwhile to note that the
clots utilized in both these studies were formed under
different conditions. Nevertheless, the dissolution of the clots
observed by L C/S-GPRP microgel conjugates can be attributed
to similar phenomena. The presence of deformable microgels
with multivalent surface display of peptides presumably
increases the probability of adjacent, dissociated knob:hole
junctions being simultaneously occupied by GPRP moieties on
the microgels, leading to an enhanced effect. Based on the
theoretical moles of AAc in the microgels, and assuming 100%
efficiency of peptide conjugation, the upper limit of GPRP
concentration in a microgel-peptide conjugate solution is in
the micromolar range. This is at least two orders of magnitude
below the free GPRP concentrations used in the
aforementioned studies. Additionally, complete clot disruption
is observed to take place in less than 3 h from the beginning of
the flow experiment. This further suggests the importance of
multivalency in the microgel approach. The difference in
disruption time seen in the two trials may be explained on the

basis of the sensitivity of this technique to small variations in
clot permeabilities. L C/S-AHRP and L C/S-GPSP microgels are
also seen to increase flow rate of solution through the clots,
indicating partial clot dissolution (Fig. 2E, D respectively).
Complete dissolution was not observed in either of these cases
within the time period of the experiment and additional
experiments need to be conducted in order to study these
processes in detail over a longer time frame. However, partial
dissolution may be attributed to non-specific interactions,
21, 22
and similarity in GPRP
weak AHRP:knob ‘B’ interactions,
and GPSP peptide sequences.
To summarize, we have developed C/S microgels with the
potential to be used as fibrinolytic agents. Flow studies
revealed size-based differential residence of these microgels in
fibrin clots. Finally, we demonstrated that conjugation of knob
‘A’ peptide mimics to the L C/S microgels generated constructs
capable of disrupting fibrin clots presumably through
competition with the knobs ‘A’ on fibrin. This competition was
for intermolecular interactions with the holes ‘a’, generated
during equilibrium dissociation and association of monomers
and/or oligomers. The multivalent display of GPRP peptides on
microgels likely plays an important role in this disruption,
leading to a faster rate of clot dissolution, at a lower overall
concentration of peptide in the dispersion, in comparison to
previous studies. These constructs thus have the ability to
target and dissolve fibrin clots. Moreover, they also have the
potential of being loaded with relevant imaging agents for
visualization of fibrin clots, or with supplemental thrombolytic
agents (proof of concept studies done with positively charged
Green Fluorescent Protein, Fig. S3 and S4, ESI), with possible
triggered, targeted release at the site of the clots, to facilitate
an even faster rate of fibrinolysis.
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EXPERIMENTAL METHODS
Materials. All materials were purchased from Sigma-Aldrich unless specified otherwise.
The primary monomer N-isopropylmethacrylamide (NIPMAm) was purified via recrystallization
from n-hexane (J.T. Baker). The following were all used as received: crosslinker

N,N′-

methylenebis(acrylamide) (BIS), comonomer used for shell synthesis acrylic acid (AAc, Fluka),
methacryloxyethyl thiocarbamoyl rhodamine B (mRhoB, Poly Fluor 570, Polysciences Inc.),
CaCl2, KCl, NaCl, anionic initiator ammonium persulfate (APS), buffer preparation materials
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sodium

dihydrogen

phosphate,

N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic
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acid)

(HEPES), 4-morpholineethanesulfonic acid (MES) and formic acid (EMD Millipore), 3aminopropyltrimethoxysilane (APTMS) for substrate functionalization for AFM imaging,
coupling reagents N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and Nhydroxysulfosuccinimide sodium salt (NHSS), 2-maleimidoethylamine trifluoroacetate salt
(AEM), human fibrinogen (FIB3, Enzyme Research Laboratories), human α-thrombin (Enzyme
Research Laboratories, HT 1002a), peptides from GenScript GPRPFPAC (GPRP), GPSPFPAC
(GPSP) and AHRPYAAC (AHRP), ethanol, isopropanol and acetone. The solutions were
prepared using distilled water, deionized to a resistance of 18 MΩ (Barnstead E-Pure system).
Solutions were filtered through a 0.2 µm Acrodisc syringe filter before use.

Microgel core synthesis. Microgel cores were synthesized by free radical precipitation
polymerization. In a typical synthesis, NIPMAm and BIS in molar compositions of 98% and 2%
respectively were dissolved in 48.5 mL distilled, deionized water, to a total monomer
concentration of 140 mM, along with SDS at the relevant concentration (refer to Table 1). The
resulting solution was filtered through a 0.8 µm Acrodisc syringe filter and introduced into a 100
mL three necked, round bottom flask along with a magnetic stirrer. The flask was fitted with a
thermometer, condenser and N2 inlet and introduced into an oil bath, which was heated at 100
°C/h. Stirring was kept constant at 400 rpm and the solution was purged with N2. Once the
temperature was stable at 70 °C, 0.5 mL of a solution of mRhoB in DMSO (final concentration
0.1 mM) was introduced into the flask, following which 1 mL of the initiator APS was added
after filtration through a 0.2 µm Acrodisc syringe filter. The reaction was allowed to proceed for
4 h under a N2 blanket, after which it was cooled down to room temperature. The solution was
then filtered through glass wool.
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Microgel shell synthesis. Core/shell microgels were synthesized using a ‘seed-and-feed’
method. The shell monomer solution was prepared by dissolving NIPMAm, BIS and AAc in
molar feed ratios of 93%, 2% and 5% respectively, in 39.5 mL distilled, deionized water, to a
total monomer concentration of 50 mM. Following the addition of SDS (final concentration: 2
mM), the resulting solution was filtered through a 0.8 µm Acrodisc syringe filter. This monomer
shell solution along with 10 mL of the respective core solution was heated to 70 °C in a manner
similar to the core synthesis and was initiated with 0.5 mL APS once temperature stability was
achieved. The synthesis was then allowed to proceed for 4 h under a N2 blanket, with constant
stirring at 400 rpm. It was then cooled down to room temperature and the solution was filtered
through glass wool. The microgels were then purified by pelleting via ultracentrifugation at
104000–417000 × g for 20–70 min, depending on the microgel type. Every run of
ultracentrifugation was followed by removal of the supernatant and resuspension in DI water.
This process was repeated six times, after which the microgels were lyophilized prior to
characterization.

Dynamic Light Scattering. Hydrodynamic radii (RH) of the microgels were determined
via dynamic light scattering (DLS, DynaPro, Protein Solutions). Measurements were performed
in the following buffers: pH 7 phosphate (50 mM ionic strength), pH 7.4 HEPES (6 mM ionic
strength), pH 3 formate (50 mM ionic strength) and pH 3 formate (6 mM ionic strength).
Microgel samples in the respective buffers were thermally equilibrated for 20 min, following
which scattering intensity fluctuations based on Brownian motion of the microgels were detected
at a scattering angle of 90°. Twenty-five (25) acquisitions of 20 s each were obtained. These were
used to generate intensity-time correlation functions, and cumulants analysis was used in order to

Biomaterials Science

attain diffusion coefficients. The Stokes-Einstein equation was then utilized to calculate RH
values. This procedure was repeated 3 more times on the same sample in order to generate a total
of 100 RH values for each microgel sample and averages of these values along with standard
deviations are presented.

Atomic Force Microscopy. Atomic Force Microscopy (AFM) was performed using an
MFP-3D AFM (Asylum Research). Images were acquired in air and under ambient conditions in
the tapping mode, using pyramidal cantilevers (Nanoworld, Force Constant 42 N/m) made of
heavily doped silicon. Image processing was performed using software written in an IgorPro
environment (Wavemetrics, Inc.)
Samples were prepared on 22 mm × 22 mm glass coverslips (VWR). The coverslips were
cleaned by sequential sonication in Alconox solution, DI water, acetone, 95% ethanol, and
isopropanol for 20 min each. They were then functionalized in a 1% (v/v) APTMS/absolute
ethanol solution on a shaker table for 2 h, following which they were washed with DI water. The
microgel solutions prepared in phosphate buffer (pH 7, 50 mM ionic strength) were then used for
submonolayer deposition onto the glass substrates by centrifugation at 2250 × g for 10–25 min
(depending on the microgel type) at 25 °C using a plate rotor. The coverslips were rinsed well
with DI water and dried with nitrogen before imaging.

Production and purification of +6 GFP. Plasmids with genes encoding for +6 GFP1
from Prof. David Liu’s research group (Howard Hughes Medical Institute, Harvard University)
were used for transformation of E.coli, following which the production and purification of the
protein was performed in a manner similar to that utilized by Cronican et al.2 with slight
modifications. Briefly, transformed E.coli were grown to an optical density of 0.6 in LB broth
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(Lennox, Alfa Aesar), following which they were induced with 1 mM IPTG (Isopropyl β-Dthiogalactopyranoside, ThermoFisher) at 30 °C for 4 h. The cells were then harvested and
preserved as pellets at −80 °C. These pellets were thawed in a solution of 1X PBS with 2 M NaCl
and sonication was employed to lyse them. Following centrifugation at 10000 × g for 8 min, the
supernatant was mixed with Ni-NTA resin (Fisher Scientific) for 30 min at 4 °C. The removal of
resin by centrifugation was followed by multiple washes with 2 M NaCl and 20 mM imidazole
(Fisher Scientific) and then a 2 M NaCl + 500 mM imidazole solution was used for detachment
of the protein from the resin. Dialysis against 1X PBS for 18 h at 4 °C was then carried out,
followed by SDS-PAGE staining with Simply Blue (ThermoFisher).

+6 GFP encapsulation studies. Lyophilized core/shell microgels were weighed and
resuspended in 0.20 µM +6 GFP solution in the respective buffer (6 mM ionic strength HEPES or
150 mM ionic strength HEPES). After a 20 h equilibration, the microgel solutions were
centrifuged at 104000–417000 × g for 20–70 min, depending on the microgel type. The
supernatants were analyzed for presence of +6 GFP by fluorescence measurements at λex = 475
nm and λem = 520 nm. Normalization was performed against stock +6 GFP solutions in the
respective buffer conditions.

Fibrin clot formation. Solutions of fibrinogen (13.51 mg/mL) and thrombin (10 U/mL)
were thawed to room temperature. The fibrinogen was mixed with CaCl2 (final concentration 5
mM), HEPES (final concentration 25 mM HEPES, 150 mM NaCl) and DI water, following
which clot formation was initiated by introducing thrombin at a final concentration of 1 U/mL.
The final concentration of fibrinogen was either 3 mg/mL (size-based localization studies) or 2
mg/mL (clot disruption studies). The clots were formed in plastic capillary tubes (Globe
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Scientific, Inc., I.D. = 0.85 mm), and were allowed to polymerize overnight in a humid
environment, to avoid abnormalities due to drying. For the perfusion experiments, they were cut
into 1.5 cm pieces for utilization with each sample solution.

Permeability measurements and perfusion studies. Flow studies were performed using
the experimental setup represented in Scheme 1. 1X HEPES buffer (same as that used for clot
preparation) was first perfused through the 1.5 cm clots. Following 15 min equilibration, flow
rates of buffer post traversal through the fibrin clots were measured for 3–5 min (depending on
the clot formation conditions), from a solution reservoir height of 18 in. Three measurements
were made for every clot and clot permeability values were calculated using Darcy’s law,
k ΔP
Q= A
μ L
where Q is the volumetric flow (m3/s), k is Darcy’s constant or the Darcy permeability (m2), µ is
the liquid viscosity (kg/ms), A is the cross-sectional area of the clot (m2), ΔP is the pressure
gradient across the clot (kg/ms2) and L is the length of the cylindrical clot (m).
Following confirmation of consistency in clot permeabilities, buffer solutions in the
reservoirs were replaced by microgel solutions at a concentration of 0.1 mg/mL and these were
allowed to flow through the clots. After equilibration for 15 min, eluent collection was begun and
was performed at 30 min intervals. The eluents were analyzed for their fluorescence using a plate
reader (Infinite® 200 PRO NanoQuant™, Tecan Group LTD., San Jose, CA) at excitation and
emission wavelengths of 540 nm and 575 nm, respectively. Following background corrections for
the buffer, fluorescence intensities normalized to those of the respective reservoir microgel
solutions (0.1 mg/mL) were calculated. Three trials were performed and values of normalized
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fluorescence intensities are presented as averages of values obtained at the respective time points
from these trials. Standard deviations were also obtained from these values and are presented.

Conjugation of peptides to microgels. L C/S microgels were divided into three sections
and resuspended in MES buffer (20 mM ionic strength). They were then conjugated to AEM
through carbodiimide coupling, using a 2X molar excess of EDC and NHSS and a 1:1 –
COOH:AEM molar ratio, based on the theoretical number of AAc moieties incorporated in the
microgel shells. This conjugation was allowed to proceed for 2 h, following which dialyses for all
three solutions were performed against MES buffer for 15 h. The MES buffer was then replaced
with phosphate buffer (pH 7, 140 mM ionic strength) and following equilibration for ~8 h,
peptide conjugations to GPRP, GPSP and AHRP (1:0.2 molar ratio of theoretical –
COOH:peptide) were performed overnight through thiol-maleimide coupling. The resulting
solutions were dialyzed against DI water for one week and placed on a shaker for homogeneity.
A small portion of each solution was lyophilized in order to determine concentration of the stock
solutions.

Clot disruption studies under flow. Clot disruption analyses were performed using a
setup similar to the one utilized for permeability measurements. 1.5 cm fibrin clots were first
analyzed for their consistency in permeability by conducting flow rate measurements using 1X
HEPES buffer. The Darcy constant k was determined for each clot, following which reservoir
buffer solutions (at an 18 in height) were replaced with the respective peptide-conjugated L C/S
microgel solutions (0.1 mg/mL). After equilibration for 10 min, flow rate measurements (3 min
each) were conducted for each microgel solution, after passage through the clot. This was
repeated every 10 min until clot disruption was observed. Pictures of clots were also taken at
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various time points during the experiment. Two separate trials were performed and the results
from these are presented.

Scheme S1. General representation of a two-step core (A) and core/shell (B) microgel synthesis
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Microgel characterization

Figure S1. DLS measurements performed on S C/S (A), I C/S (B) and L C/S (C) microgels generated RH
values that demonstrated a slightly greater magnitude of pH responsivity at 6 mM ionic strength, than at
50 mM ionic strength, due to partial screening of charges in the presence of a higher concentration of ionic
species in solution.

Figure S2. AFM height traces of S C/S, I C/S and L C/S microgels deposited on APTMS-functionalized
glass by centrifugal deposition at 2250 × g for 10–25 min at 25 °C, depending on the microgel type.
Particles in all three size ranges were spherical and the differences in microgel size were evident from the
images and height profiles.
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Production of +6 GFP

Figure S3. SDS-PAGE of purified +6 GFP. Based on the molecular weight standards (A), the bands
represent the presence of +6 GFP (molecular weight of GFP is 27 kDa) 3. B and C represent the +6 GFP
solutions before and after dialysis, respectively.
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Analysis of +6 GFP encapsulation in core/shell microgels

Figure S4. Analysis of encapsulation of +6 GFP by S C/C, I C/S and L C/S microgels.

Fluorescence intensities of supernatants were normalized to those of +6 GFP solutions in the
respective buffers. Charge screening at higher (150 mM) ionic strength was found to be effective
in causing differential encapsulation (Values presented as averages of 3 measurements on single
samples, error bars represent standard deviations in these three values).

This analysis revealed that the size of +6 GFP (~ 27 kDa) is in a range that allows passage
into microgels with the crosslinking density used in these experiments. Thus, encapsulation of
other proteins with dimensions similar to +6 GFP into microgels may be feasible. Additionally,
these results also indicate that charge interactions play an important role in this encapsulation.
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Figure S2. AFM height traces of S C/S, I C/S and L C/S microgels deposited on APTMS-functionalized glass
by centrifugal deposition at 2250 × g for 10–25 min at 25 °C, depending on the microgel type. Particles in
all three size ranges were spherical and the differences in microgel size were evident from the images and
height profiles.
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